Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Mar 1;97(5):1286–1292. doi: 10.1172/JCI118544

Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction.

A L Clavell 1, M T Mattingly 1, T L Stevens 1, A Nir 1, S Wright 1, L L Aarhus 1, D M Heublein 1, J C Burnett Jr 1
PMCID: PMC507182  PMID: 8636441

Abstract

Endothelin (ET) is a potent vasoconstrictor peptide which is elevated in plasma in congestive heart failure. Recent studies suggest an important role for angiotensin II (AII) in the activation of ET in cultured cardiomyocytes. Chronic thoracic inferior vena caval constriction (TIVCC) is a model of reduced cardiac output that mimics the neurohumoral activation observed in congestive heart failure. We hypothesized that activation of the renin-angiotensin system in TIVCC plays a role in the activation of ET and that the elevation of endogenous ET contributes to the systemic and renal vasoconstriction that characterizes this model of venous congestion. We studied conscious dogs after 7 d of TIVCC in the presence or absence of chronic angiotensin converting enzyme inhibition with enalapril. TIVCC resulted in marked activation of plasma AII and ET in plasma, right atrium, lung, and renal medulla which was further localized to cardiomyocytes, pulmonary, and renal epithelial cells. Chronic angiotensin converting enzyme inhibition abolished the increases in plasma AII and ET during TIVCC. Acute endothelin A receptor blockade with FR-139317 resulted in significant decreases in mean arterial pressure and systemic vascular resistance in TIVCC. We conclude that activation of the renin-angiotensin system contributes to the activation of circulating and local ET in TIVCC and that this activation plays an important role in the regulation of arterial pressure and systemic vascular resistance in this model of congestive failure.

Full Text

The Full Text of this article is available as a PDF (6.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Boulanger C., Lüscher T. F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990 Feb;85(2):587–590. doi: 10.1172/JCI114477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burnett J. C., Jr, Kao P. C., Hu D. C., Heser D. W., Heublein D., Granger J. P., Opgenorth T. J., Reeder G. S. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986 Mar 7;231(4742):1145–1147. doi: 10.1126/science.2935937. [DOI] [PubMed] [Google Scholar]
  4. Clavell A. L., Stingo A. J., Margulies K. B., Brandt R. R., Burnett J. C., Jr Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol. 1995 Mar;268(3 Pt 2):F455–F460. doi: 10.1152/ajprenal.1995.268.3.F455. [DOI] [PubMed] [Google Scholar]
  5. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  6. Cristol J. P., Warner T. D., Thiemermann C., Vane J. R. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol. 1993 Mar;108(3):776–779. doi: 10.1111/j.1476-5381.1993.tb12877.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Firth J. D., Ratcliffe P. J. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest. 1992 Sep;90(3):1023–1031. doi: 10.1172/JCI115915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Freeman R. H., Davis J. O., Williams G. M., DeForrest J. M., Seymour A. A., Rowe B. P. Effects of the oral converting enzyme inhibitor, SQ 14225, in a model of low cardiac output in dogs. Circ Res. 1979 Oct;45(4):540–545. doi: 10.1161/01.res.45.4.540. [DOI] [PubMed] [Google Scholar]
  9. Garcia N. H., Garvin J. L. Endothelin's biphasic effect on fluid absorption in the proximal straight tubule and its inhibitory cascade. J Clin Invest. 1994 Jun;93(6):2572–2577. doi: 10.1172/JCI117268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  11. Ito H., Hirata Y., Adachi S., Tanaka M., Tsujino M., Koike A., Nogami A., Murumo F., Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993 Jul;92(1):398–403. doi: 10.1172/JCI116579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kohan D. E. Endothelin production by human inner medullary collecting duct cells. J Am Soc Nephrol. 1993 Apr;3(10):1719–1721. doi: 10.1681/ASN.V3101719. [DOI] [PubMed] [Google Scholar]
  13. Kohan D. E., Padilla E. Osmolar regulation of endothelin-1 production by rat inner medullary collecting duct. J Clin Invest. 1993 Mar;91(3):1235–1240. doi: 10.1172/JCI116286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kohno M., Yokokawa K., Horio T., Yasunari K., Murakawa K., Takeda T. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992 Feb;70(2):241–247. doi: 10.1161/01.res.70.2.241. [DOI] [PubMed] [Google Scholar]
  15. Kourembanas S., Marsden P. A., McQuillan L. P., Faller D. V. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest. 1991 Sep;88(3):1054–1057. doi: 10.1172/JCI115367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lerman A., Edwards B. S., Hallett J. W., Heublein D. M., Sandberg S. M., Burnett J. C., Jr Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991 Oct 3;325(14):997–1001. doi: 10.1056/NEJM199110033251404. [DOI] [PubMed] [Google Scholar]
  17. Lerman A., Kubo S. H., Tschumperlin L. K., Burnett J. C., Jr Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol. 1992 Oct;20(4):849–853. doi: 10.1016/0735-1097(92)90183-n. [DOI] [PubMed] [Google Scholar]
  18. Margulies K. B., Hildebrand F. L., Jr, Lerman A., Perrella M. A., Burnett J. C., Jr Increased endothelin in experimental heart failure. Circulation. 1990 Dec;82(6):2226–2230. doi: 10.1161/01.cir.82.6.2226. [DOI] [PubMed] [Google Scholar]
  19. Masaki T., Kimura S., Yanagisawa M., Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation. 1991 Oct;84(4):1457–1468. doi: 10.1161/01.cir.84.4.1457. [DOI] [PubMed] [Google Scholar]
  20. Miyauchi T., Yanagisawa M., Tomizawa T., Sugishita Y., Suzuki N., Fujino M., Ajisaka R., Goto K., Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989 Jul 1;2(8653):53–54. doi: 10.1016/s0140-6736(89)90303-6. [DOI] [PubMed] [Google Scholar]
  21. Momose N., Fukuo K., Morimoto S., Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension. 1993 Jun;21(6 Pt 2):921–924. doi: 10.1161/01.hyp.21.6.921. [DOI] [PubMed] [Google Scholar]
  22. Nir A., Clavell A. L., Heublein D., Aarhus L. L., Burnett J. C., Jr Acute hypoxia and endogenous renal endothelin. J Am Soc Nephrol. 1994 May;4(11):1920–1924. doi: 10.1681/ASN.V4111920. [DOI] [PubMed] [Google Scholar]
  23. Nunez D. J., Brown M. J., Davenport A. P., Neylon C. B., Schofield J. P., Wyse R. K. Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest. 1990 May;85(5):1537–1541. doi: 10.1172/JCI114601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Paganelli W. C., Cant J. R., Pintal R. R., Kifor I., Barger A. C., Dzau V. J. Plasma atrial natriuretic factor during chronic thoracic inferior vena caval constriction. Circ Res. 1988 Feb;62(2):279–285. doi: 10.1161/01.res.62.2.279. [DOI] [PubMed] [Google Scholar]
  25. Pollock D. M., Opgenorth T. J. Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. Am J Physiol. 1993 Jan;264(1 Pt 2):R222–R226. doi: 10.1152/ajpregu.1993.264.1.R222. [DOI] [PubMed] [Google Scholar]
  26. Saito Y., Nakao K., Mukoyama M., Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med. 1990 Jan 18;322(3):205–205. doi: 10.1056/nejm199001183220315. [DOI] [PubMed] [Google Scholar]
  27. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  28. Sandok E. K., Lerman A., Stingo A. J., Perrella M. A., Gloviczki P., Burnett J. C., Jr Endothelin in a model of acute ischemic renal dysfunction: modulating action of atrial natriuretic factor. J Am Soc Nephrol. 1992 Aug;3(2):196–202. doi: 10.1681/ASN.V32196. [DOI] [PubMed] [Google Scholar]
  29. Smith H. W., Finkelstein N., Aliminosa L., Crawford B., Graber M. THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. J Clin Invest. 1945 May;24(3):388–404. doi: 10.1172/JCI101618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Stingo A. J., Clavell A. L., Aarhus L. L., Burnett J. C., Jr Biological role for the endothelin-A receptor in aortic cross-clamping. Hypertension. 1993 Jul;22(1):62–66. doi: 10.1161/01.hyp.22.1.62. [DOI] [PubMed] [Google Scholar]
  31. Teerlink J. R., Breu V., Sprecher U., Clozel M., Clozel J. P. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res. 1994 Jan;74(1):105–114. doi: 10.1161/01.res.74.1.105. [DOI] [PubMed] [Google Scholar]
  32. Teerlink J. R., Löffler B. M., Hess P., Maire J. P., Clozel M., Clozel J. P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation. 1994 Nov;90(5):2510–2518. doi: 10.1161/01.cir.90.5.2510. [DOI] [PubMed] [Google Scholar]
  33. Underwood R. D., Aarhus L. L., Heublein D. M., Burnett J. C., Jr Endothelin in thoracic inferior vena caval constriction model of heart failure. Am J Physiol. 1992 Sep;263(3 Pt 2):H951–H955. doi: 10.1152/ajpheart.1992.263.3.H951. [DOI] [PubMed] [Google Scholar]
  34. Watkins L., Jr, Burton J. A., Haber E., Cant J. R., Smith F. W., Barger A. C. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest. 1976 Jun;57(6):1606–1617. doi: 10.1172/JCI108431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES